Catheter securement devices are used primarily in acute care facilities to reduce restarts and complications associated with peripheral intravenous (IV) catheters. They are similarly used in conjunction with central venous and peripherally inserted central catheters (PICCs), Foley and dialysis catheters, nasogastric (NG) tubes and other catheter-based devices. Today, the
Timothy M. Ring, chairman and CEO, commented, "The StatLock catheter securement devices and associated technology fit very well strategically with several of our market leading product lines. StatLock devices have strong brand recognition and come with an extensive intellectual property portfolio that includes 245 patents and patent applications. Additionally, the product line is supported by multiple clinical and economic outcomes studies. We look forward to the Venetec organization becoming part of Bard and to the contribution their product line will make to our long-term growth strategy."
Based on expected completion of the transaction in the second quarter, the company is raising its full-year 2006 constant currency revenue growth guidance by one percentage point to a range of 10 to 11 percent. Full-year 2006 diluted earnings per share growth guidance of a minimum of 14 percent, excluding items that impact the comparability of results between periods and the impact of FAS123R, remains unchanged.
C. R. Bard, Inc., headquartered in Murray Hill, N.J., is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.